OKYO Pharma Limited (OKYO)
NASDAQ: OKYOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
OKYO stock chart
Technical analysisKey statistics
All statistics- Market cap
- $56.15M
- EPS (TTM)
- -$0.24
- Dividend yield
- None
- 52-week range
- 1.00 – 3.20
- Day range
- 1.04 – 1.25
- Volume / Avg
- 76.39K / 143.41K
- Beta
- —
- Shares outstanding
- 52.48M
52-week range
OKYO stock today
OKYO Pharma (OKYO) closed at $1.07 on Nov 20, down 7.76% (-$0.09), versus the S&P 500's 3.70% decline. At this level, OKYO sits near the bottom of its 52-week range of $1.00 to $3.20: 66.6% below the high, set on Jan 14, 2026 and 7.0% above the low. OKYO is down 48.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 49.5%.
OKYO Pharma has posted a net loss over the last twelve months (EPS of -$0.24), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About OKYO Pharma
Company profileOKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Robert J. Dempsey M.B.A.
- Headquarters
- London
- Employees
- 5
- IPO year
- 2022
- Website
- okyopharma.com
Financial highlights
Full financialsOKYO Pharma reported a net loss of $4.7 million, compared with a loss of $16.8 million a year earlier. Diluted earnings per share came in at -$0.20.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-4.71M | $-16.83M | $-13.27M | $-5.43M | $-3.35M |
| EPS (diluted) | $-0.20 | $-0.57 | $-0.61 | $-0.36 | $-0.32 |
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$8.33+678.50%
- Strong buy 1
- Buy 2
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
OKYO Pharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CGTXCognition Therapeutics Inc. | 0.5822 | -3.06% | $55.37M | vs OKYO |
| CHRSCoherus Oncology Inc. | 0.3698 | -4.47% | $57.15M | vs OKYO |
| AVXLAnavex Life Sciences Corp. | 0.5915 | -11.39% | $54.83M | vs OKYO |
| CSBRChampions Oncology Inc. | 4.34 | -1.36% | $60.41M | vs OKYO |
| NMRANeumora Therapeutics Inc. | 0.3339 | -3.78% | $63.01M | vs OKYO |
| IMAImageneBio Inc. | 3.92 | 0.00% | $48.83M | vs OKYO |
| ATRAAtara Biotherapeutics Inc. | 6.33 | -0.16% | $64.49M | vs OKYO |
| TNYATenaya Therapeutics Inc. | 0.2866 | -3.99% | $65.32M | vs OKYO |
Indexes, lists and sector
OKYO Pharma stock FAQ
What is OKYO Pharma's stock price today?
OKYO last traded at $1.07 as of Nov 20, 4:00 PM EST, down 7.76% on the day. Prices are delayed at least 15 minutes.
Who is OKYO Pharma's CEO?
Mr. Robert J. Dempsey M.B.A. is the chief executive officer of OKYO Pharma Limited, which has about 5 employees.
What is the OKYO 52-week high?
The 52-week high for OKYO is $3.20 and the 52-week low is $1.00. The stock is currently 66.6% below its high.